PLEKHA6

Across TCGA pan-cancer cohorts, PLEKHA6 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PLEKHA6 data layer compared with 27 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher PLEKHA6 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PLEKHA6 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

OV, KIRC, and LIHC are the cancer types where PLEKHA6 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	OS	Median	II,III,IV	0.028	0.844	<.001	48	view →
KIRC	DFS	Median	All	0.133	0.796	<.001	36	view →
LIHC	DFS	Median	III,IV	0.076	0.360	.001	24	view →
UCEC	DFS	Median	II,III,IV	0.933	0.436	.018	14	view →
CHOL	OS	Median	All	0.155	0.725	.029	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PLEKHA6–OV (OS)

Open the OV breakdown →